Evidence map›Paper›PMID 36430445›Full record

ArticleInternational journal of molecular sciences2022

A Novel 3D Culture Scaffold to Shorten Development Time for Multicellular Tumor Spheroids.

Cian-Ru Yang, Chu-Ting Liang, Shih-Chieh Tsai, Yu-Chun Wu, Ching-Wen Liu, Hui-Hua Yang, Ting-Yuan Tu, Yueh-Chun Lee, Kuei-Yang Hsiao, Wei-Chun Chang and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Cian-Ru YangPh.D. Program for Health Science and Industry, China Medical University, Taichung 404, Taiwan.
Chu-Ting LiangGEcoll Biomedical Co., Ltd., Tainan Science Park, Tainan 744, Taiwan.
Shih-Chieh TsaiGEcoll Biomedical Co., Ltd., Tainan Science Park, Tainan 744, Taiwan.
Yu-Chun WuGEcoll Biomedical Co., Ltd., Tainan Science Park, Tainan 744, Taiwan.
Ching-Wen LiuGEcoll Biomedical Co., Ltd., Tainan Science Park, Tainan 744, Taiwan.
Hui-Hua YangBioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan.
Ting-Yuan TuDepartment of Biomedical Engineering, National Cheng Kung University, Tainan 701, Taiwan.ORCID 0000-0002-1816-4615
Yueh-Chun LeeSchool of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.ORCID 0000-0002-9713-9708
Kuei-Yang HsiaoInstitute of Biochemistry, College of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan.ORCID 0000-0002-1648-974X
Wei-Chun ChangPh.D. Program for Health Science and Industry, China Medical University, Taichung 404, Taiwan.
Wen-Lung MaPh.D. Program for Health Science and Industry, China Medical University, Taichung 404, Taiwan.ORCID 0000-0002-5571-3302
China Medical University · TWAsia University · TWChung Shan Medical University · TWNational Cheng Kung University · TWNational Chung Hsing University · TWTzu Chi Foundation · TW

Funding

China Medical University/Hospital DMR-108-079, DMR-109-086, DMR-109-019, CMU109-MF-26, CMU111-MF-91, DMR-111-118, DMR-111-238, DMR-110-025, DMR-111-204Hsing Chung inter-institutional project NCHU-CSMU-10805, NCHU-CSMU-10906, NCHU-CSMU-11007National Health Research Institutes NHRI-EX111-11110BITaiwan Ministry of Science and Technology MOST 109-2327-B-039-002, MOST 109-2320-B-039-006, MOST 108-2314-B-039-042-MY3, MOST 108-2314-B-039-043-MY3, MOST 111-2320-B-039-011, MOST 111-2314-B-039-062-MY3, MOST 110-2314-B-039-046, MOST 109-2320-B-005-008-MY3
6 · The paper itself

Abstract

Multicellular tumor spheroids and tumoroids are considered ideal in vitro models that reflect the features of the tumor microenvironment. Biomimetic components resembling the extracellular matrix form scaffolds to provide structure to 3-dimensional (3D) culture systems, supporting the growth of both spheroids and tumoroids. Although Matrigel has long been used to support 3D culture systems, batch variations, component complexity, and the use of components derived from tumors are complicating factors. To address these issues, we developed the ACD 3D culture system to provide better control and consistency. We evaluated spheroid and tumoroid formation using the ACD 3D culture system, including the assessment of cell viability and cancer marker expression. Under ACD 3D culture conditions, spheroids derived from cancer cell lines exhibited cancer stem cell characteristics, including a sphere-forming size and the expression of stem cell marker genes. The ACD 3D culture system was also able to support patient-derived primary cells and organoid cell cultures, displaying adequate cell growth, appropriate morphology, and resistance to oxaliplatin treatment. These spheroids could also be used for drug screening purposes. In conclusion, the ACD 3D culture system represents an efficient tool for basic cancer research and therapeutic development.

Indexed as

NeoplasmsSpheroids, CellularCell Culture TechniquesCell LineHumansStem CellsTumor Microenvironment3D scaffold culturecancer stem cellmulticellular tumor spheroid

Identifiers

PMID36430445
PMCPMC9699299
OpenAlexW4308973193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.